ClinicalTrials.gg
CompletedNCT04539041Updated Dec 24, 2025

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

A Phase 1 interventional study of antisense oligonucleotide and placebo in Progressive Supranuclear Palsy (PSP), sponsored by Novartis Pharmaceuticals. Completed at 12 sites in 4 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Supranuclear Palsy, Progressive with a site in Germany — 4 open to participants now, 5 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · Germany.

Enrollment
10th of 18
59 · median 67
Started
2021
with 2 others
Phase 1
5 of 21
none open now
Registered
11th of 21
by date
Lead sponsor
2 of 21
Novartis Pharmaceuticals

Among the 21 studies in Supranuclear Palsy, Progressive with a site in Germany, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2021, is one of 5 in phase 1, and was the 11th registered.

Supranuclear Palsy, Progressive

171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.

Browse Supranuclear Palsy, Progressive studies →

Open to participants now

4 of the 21 studies in Supranuclear Palsy, Progressive with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Supranuclear Palsy, Progressive with a site in Germany, or all of them as a file.
02

Study summary

This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.

Read the detailed description

This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.

Approximately 58 PSP participants in 5 cohorts will be randomized to receive NIO752 or placebo in a ratio of 3:1. Intrathecal (IT) injections will be given multiple times over 3 months and participants will remain in study for an additional 9-month follow-up period; or will be given multiple times over 9 months and participants will remain in study for an additional 3-month follow-up period.

Cohorts will be enrolled sequentially.

Safety assessments will include physical and neurological examinations, ECGs, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, and urinalysis), CSF laboratory test, adverse event, and serious adverse event monitoring.

03

Conditions studied

  • Progressive Supranuclear Palsy (PSP)

Keywords

  • progressive supranuclear palsy
  • PSP
  • antisense oligonucleotide
  • ASO
  • tau
  • NIO752
  • adult
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Between 40 to 75 years old (inclusive)
  3. Have PSP diagnosed for less than 5 years with a current classification of probable PSP Richardson syndrome, a progressive supranuclear palsy rating scale (PSPRS) score \< 40 and MOCA score >17 at screening
  4. Be able to ambulate independently or able to take at least 5 steps with minimal assistance
  5. At least a 12-month history of postural instability or falls within 3 years from disease onset as per medical history
  6. Vertical supranuclear gaze palsy, or reduced velocity of vertical saccade
  7. Able and willing to meet all study requirements including:

    Have a study partner who is reliable, competent, and at least 18 years of age, and will be able to accompany the participant to study visits, be knowledgeable of the participant's ongoing condition during the study to provide study related information to study site when required both in person and via a phone Reside in a proximity to the study site to allow a timely unscheduled visit if necessary (ideally less than 2 hours) Able to undergo lumbar puncture (LP), CSF draws and blood draws

  8. If the participant is receiving levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, catechol-o-methyltransferase (COMT) inhibitor, rasagiline, CoQ10 or other Parkinson's medications, acetylcholinesterase inhibitors, antipsychotics, memantine, or other non-tau modifying Alzheimer's medication the dose must have been stable for at least 30 days prior to the screening visit and must remain stable for the duration of the study. No such medication can be initiated during the study.

Exclusion criteria

Exclusion Criteria:

  1. Live in a skilled nursing facility or dementia care facility
  2. Evidence of motor neuron disease, or any other neurological disease that could explain symptoms
  3. laboratory abnormality
  4. Attempted suicide, suicidal ideation with a plan that required hospital admission within 12 months prior to Screening. In addition, patients deemed by the Investigator to be at significant risk of suicide, major depressive episode, psychosis, confusion state, or violent behavior should be excluded.
  5. A clear and robust benefit from levodopa by history
  6. Use of lithium, methylene blue or other putative disease modifying drugs for PSP within 30 days of screening
  7. Any previous use of experimental therapy within 30 days or 5 half-lives prior to Day 1, whichever is greater
  8. Any condition that increases risk of meningitis unless participant is receiving appropriate prophylactic treatment
  9. History of post-lumbar-puncture headache of moderate or severe intensity and/or blood patch

11. Hospitalization for any major medical or surgical procedure involving general anesthesia within 12 weeks of Screening or planned during the study 12. Unable to undergo magnetic resonance imaging (MRI) due to for example claustrophobia, or presents absolute to MRI (e.g., metallic implants, metallic foreign bodies, pacemaker, defibrillator) 13. Patients with other significant brain MRI abnormalities by history or at screening.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Cohort A NIO752

    4 injections of NIO752 at dose A

    Drug: antisense oligonucleotide

  • Experimental
    Cohort B NIO752

    4 injections of NIO752 at dose B

    Drug: antisense oligonucleotide

  • Placebo comparator
    Placebo

    4 injections of placebo

    Drug: placebo

  • Experimental
    Cohort C NIO752

    4 injections of NIO752 at dose C

    Drug: antisense oligonucleotide

  • Experimental
    Cohort D NIO752

    4 injections of NIO752 at dose D

    Drug: antisense oligonucleotide

  • Experimental
    Cohort E NIO752

    4 injections of NIO752 at dose E

    Drug: antisense oligonucleotide

Interventions

  • Drugantisense oligonucleotide

    solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels

    Also known as: NIO752

  • Drugplacebo

    placebo for each dose level

06

What researchers measure

Primary outcomes

  1. Number of adverse events and serious adverse events

    Adverse events will be collected at clinical visits and other contacts. All abnormalities from safety assessments (physical exams and neurological exams and clinical safety labs) considered clinically significant will be recorded as adverse events

    Time frame: Baseline up to approximately one year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)

  2. Change in severity scores for Columbia-Suicide Severity Rating Scale (C-SSRS)

    The Columbia-Suicide Severity Rating Scale (C-SSRS) is a questionnaire that prospectively assesses Suicidal Ideation and Suicidal Behavior. The C-SSRS must be administered at visits. If, at any time after "screening and/or baseline" version, the score is "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS or "yes" on any item of the Suicidal Behavior section, the participant must be referred to a mental health care professional for further assessment and/or treatment.

    Time frame: Baseline up to approximately 1 year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)

  3. Levels of infection indicators in Cerebrospinal fluid (CSF)

    CSF safety labs measure levels of proteins, glucose, lactate and white blood cell counts with differential indicating infections.

    Time frame: Baseline up to approximately 1 year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)

Secondary outcomes

  1. Concentrations of NIO752 in blood plasma

    concentrations of NIO752 in plasma

    Time frame: From the 1st dose administration (day 1), through study completion, where the longest duration would be approximately 1 year for those who receive 4 treatment doses

  2. Concentrations of NIO752 in CSF

    concentrations of NIO752 in CSF

    Time frame: From the 1st dose administration (day 1), through study completion, where the longest duration would be approximately 1 year for those who receive 4 treatment doses

  3. Cmax, Ctrough in blood plasma

    Maximum and trough level concentrations of NIO752 in plasma

    Time frame: From the 1st dose administration (day 1), through study completion, where the longest duration would be approximately 1 year for those who receive 4 treatment doses

  4. Tmax in blood plasma

    Time of Cmax in plasma post first injection

    Time frame: From the 1st dose administration (day 1), through study completion, where the longest duration would be approximately 1 year for those who receive 4 treatment doses

  5. AUClast in blood plasma

    Area under curve (AUC) from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)

    Time frame: 0 to 24 hours after first injection

  6. AUCinf in blood plasma

    The AUC from time zero to infinity (mass x time x volume-1)

    Time frame: 0 to 24 hours after first injection

07

Study locations

12 sites
  • University of California San Diego
    La Jolla, California 92037, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Vanderbilt University Medical CenterX
    Nashville, Tennessee 37221, United States
  • Novartis Investigative Site
    Montreal, Quebec H2X 1R9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3A 2B4, Canada
  • Novartis Investigative Site
    Bonn, North Rhine-Westphalia 53127, Germany
  • Novartis Investigative Site
    Düsseldorf, 40225, Germany
  • Novartis Investigative Site
    Hanover, 30625, Germany
  • Novartis Investigative Site
    München, 81377, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
08

References and documents

Publications

  • Rahim AA, Kurian MA, Zhou H, Ferguson R, Tabrizi SJ, Lignani G, Aquilina K, Waddington SN. Genetic therapies for neurological diseases. Pharmacol Rev. 2026 Jan;78(1):100093. doi: 10.1016/j.pharmr.2025.100093. Epub 2025 Oct 3. PubMed 41389437 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Oct 2024, 44 months.

Of 15 phase 1 interventional studies under Supranuclear Palsy, Progressive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 23. This study's 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Sep 4, 2020
StartActual
Feb 16, 2021
Primary completionActual
Oct 17, 2024
CompletionActual
Oct 17, 2024
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04539041
Responsible party
Sponsor
First posted
Sep 4, 2020
Start date
Feb 16, 2021
Primary completion
Oct 17, 2024
Completion
Oct 17, 2024
Last update
Dec 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion